Delivery Order SPE2DR25D6029-SPE2DR26FXP8X
- Not listed
- The Defense Logistics Agency awarded a $6,672.74 firm fixed price delivery order to AmerisourceBergen Drug Corp for Crexont ER 87.5 mg-350 mg capsules (120 count) on September 5, 2025, with completion targeted for September 8, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $6,966.32 to AmerisourceBergen Drug Corp for CREXONT ER 52.5 mg–210 mg capsules (120 count). The contract, executed on October 27, 2025, with an ultimate completion date of October 28, 2025, utilizes a firm fixed price structure with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $2,881.19 delivery order to AmerisourceBergen Drug Corp for Crexont ER 87.5 mg-350 mg capsules (120 count) on August 21, 2025, with ultimate completion by August 22, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract utilizing competitively-awarded pricing. The product will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $5,255.04 to AmerisourceBergen Drug Corp for Crexont ER 87.5 mg-350 mg capsules (120 count) on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed price contract was issued without a set-aside designation and will be performed at AmerisourceBergen's location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,501.63 to AmerisourceBergen Drug Corp for Crexont ER 70 MG-280 MG capsules (120-count supply) on August 4, 2025, with completion scheduled for August 5, 2025. This non-competitive delivery order utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical supplier to federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for CREXONT ER 52.5 MG-210 MG capsules (120-count) on May 20, 2025, with a ceiling value of $2,394.89 and firm fixed pricing. This competitive award, which carries no set-aside designation, is classified as a child contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single pharmaceutical procurement transaction under the...
- The Defense Logistics Agency awarded a delivery order valued at $4,030.34 to AmerisourceBergen Drug Corp for the supply of CREXONT ER 87.5 MG-350 MG capsules (120 count) on October 21, 2025, with an ultimate completion date of October 22, 2025. This delivery order represents a firm fixed price contract with no set-aside designation, issued under open competition. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is...
- This is a Delivery Order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,315.07, is for the delivery of 4567615784 ! CREXONT ER 87.5 MG-350 MG CAP 120S, a medical product, with a performance period ending on March 19, 2025. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with...
- The Defense Logistics Agency awarded a $11.7K delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of CREXONT ER 52.5 MG-210 MG capsules (120-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of April 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,162.02 firm-fixed-price contract is for the delivery of CREXONT ER 52.5 MG-210 MG capsules, with a completion date of March 26, 2025. The contract is not designated as a set-aside and is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop...
- SPE2DR25D6029Indefinite Delivery Contract
- SPE2DR25D6029-SPE2DR26FXP8XDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,461.53 to AmerisourceBergen Drug Corp for Crexont ER (52.5 mg-210 mg capsules, quantity 120) with a firm fixed price contract type. The award, issued on October 31, 2025, is non-competitive with an ultimate completion date of November 3, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, fulfills this order as part of its comprehensive pharmaceutical supply mission supporting military and veteran healthcare systems. The company's broader federal contract portfolio demonstrates extensive experience delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This transaction reflects the company's ongoing role as a primary pharmaceutical supplier within DLA's global medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.5k | 10/31/25 |